The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy

NCT00687453 Phase 4 TERMINATED Results posted

To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.

Details

Lead sponsor	Charles Drew University of Medicine and Science
Phase	Phase 4
Status	TERMINATED
Enrolment	27
Start date	2003-02
Completion	2009-08

Conditions

• Type 2 Diabetes Mellitus

Interventions

• Insulin glargine at bedtime instead of NPH
• NPH twice-daily

Primary outcomes

• Hemoglobin A1c Change From Baseline — Baseline to 6 months

Countries

United States